SOAT1 and psoriasis: Activation of JAK/STAT is characteristic and strongly expressed in psoriatic disease, hence JAK inhibitors (i.a., baricitinib, ruxolitinib, upadicitinib, cerdulatinib) have established therapeutic effects in psoriasis [15,59,60].